New music video on results from the START study: “Now we know”
1 October 2015. Related: On the web.
2015
UK PROUD study published as open access article in the Lancet
1 October 2015. Related: On the web.
“We will win or lose the fight against AIDS in next five years”: UNAIDS and Lancet commission report
1 August 2015. Related: Treatment access, On the web.
July/Aug 2015: Volume 16 Number 7/8
1 August 2015. Related: Editorial.
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2015), 19 – 22 July 2015, Vancouver, Canada
1 August 2015. Related: Conference reports.
Tribute to Bob Munk: long-time HIV positive US treatment activist and educator
1 August 2015. Related: In memory, Conference reports.
Four reasons IAS 2015 will be a milestone HIV conference: a personal view
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies, HIV prevention and transmission.
Starting HIV treatment at high CD4 counts protects against both AIDS and non-AIDS events: overall and in subgroup analyses of START study
1 August 2015. Related: Conference reports, Antiretrovirals, Treatment strategies.
The option for same day antiretroviral therapy on diagnosis: the future model for HIV care
1 August 2015. Related: Conference reports, Treatment strategies, Treatment access, Treatment advocacy, Other news.
Pipeline ARVs at IAS 2015: doravirine, BMS-955176 and BMS-663068
1 August 2015. Related: Conference reports, Antiretrovirals.
New directions in the 2015 WHO ART guidelines
1 August 2015. Related: Conference reports, Treatment access, Guidelines.
Rapid implementation of the 2013 WHO ART guidelines
1 August 2015. Related: Conference reports, Antiretrovirals, Guidelines.
Large variation across countries in meeting UNAIDS 90-90-90 targets
1 August 2015. Related: Conference reports, Treatment access.
Low dose boosted atazanavir is non-inferior to standard dose in Thai treatment optimisation study: LASA
1 August 2015. Related: Conference reports, Treatment strategies.
HPTN 052: no HIV transmissions on effective ART but only limited data on viral failure and drug resistance
1 August 2015. Related: Conference reports, Treatment strategies, HIV prevention and transmission.
Dispersible tablet formulation of dolutegravir is bioequivalent to the granule formulation
1 August 2015. Related: Conference reports, Paediatric care.
New case of remission in a perinatally infected teenager
1 August 2015. Related: Conference reports, Cure-related research.
IAS 2015: accessing webcasts and abstracts online
1 August 2015. Related: Conference reports.
IAS Towards an HIV Cure symposium, 18 – 19 July 2015, Vancouver, Canada
1 August 2015. Related: Conference reports, Cure-related research.
Plenary talks at IAS Cure Workshop
1 August 2015. Related: Conference reports, Cure-related research.
Rilpivirine/FTC/TAF becomes the third TAF-based fixed dose combination submitted for US approval
1 August 2015. Related: Antiretrovirals.
Draft BHIVA treatment guidelines (2015): the most significant changes for a decade
1 August 2015. Related: Guidelines.
Innate immunity and HIV DNA declines in panobinostat recipients
1 August 2015. Related: Cure-related research, Basic science and immunology.
Comprehensive review of DAA research at EASL
1 August 2015. Related: Hepatitis coinfection.
RITA online: feature on bone health
1 August 2015. Related: On the web.
Involving people in services: a guide to why and how
1 August 2015. Related: On the web.
July/August 2015: Volume 16 Number 7/8
1 August 2015. Related: PDFs.
HTB supplement: 2015 Pipeline Report
17 July 2015. Related: Special reports, Pipeline report.
Dedication
17 July 2015. Related: Pipeline report.
The antiretroviral pipeline 2015
17 July 2015. Related: Pipeline report, Antiretrovirals.
Fit for purpose: antiretroviral treatment optimisation 2015
17 July 2015. Related: Pipeline report, Fit for purpose, Antiretrovirals.
The Pediatric Antiretroviral Pipeline
17 July 2015. Related: Pipeline report, Antiretrovirals, Paediatric care.
Preventive Technologies: Antiretroviral and Vaccine Development
17 July 2015. Related: Pipeline report, Vaccines and microbicides.
Research Toward a Cure and Immune-Based and Gene Therapies
17 July 2015. Related: Pipeline report, Cure-related research.
New Drugs, New Strategies: Conquering Hepatitis C with Direct-Acting Antivirals
17 July 2015. Related: Pipeline report, Hepatitis coinfection.
The Tuberculosis Treatment Pipeline: Moving Beyond “Making the Most of What We’ve Got”
17 July 2015. Related: Pipeline report, TB coinfection.
Momentum in the Pediatric Tuberculosis Treatment Pipeline
17 July 2015. Related: Pipeline report, Paediatric care, TB coinfection.
The Tuberculosis Diagnostics Pipeline
17 July 2015. Related: Pipeline report, Diagnostics, TB coinfection.
The Tuberculosis Vaccines Pipeline: A New Path to the Same Destination?
17 July 2015. Related: Pipeline report, TB coinfection, Vaccines and microbicides.
May/June 2015: Volume 16 Number 5/6
1 June 2015. Related: PDFs.
May/June 2015: Volume 16 Number 5/6
1 June 2015. Related: Editorial.
Remembering Professor Martin Fisher
1 June 2015. Related: In memory.
Early START results recommend ART for all study participants: starting HIV meds when the CD4 count is above 500 reduces AIDS-related events
1 June 2015. Related: Treatment alerts.
21st Annual BHIVA Conference, 21-24 April 2015, Brighton
1 June 2015. Related: Conference reports.
BHIVA pregnancy audit 2013 to 2014
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy.
Transmitted drug resistance in HIV positive pregnant women
1 June 2015. Related: Conference reports, Pregnancy, Drug resistance.
Primary HIV infection and early use of ART
1 June 2015. Related: Conference reports, Antiretrovirals.
Rectal STIs and viral load in HIV positive men on and off ART
1 June 2015. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Impact of age and HIV on use of non-HIV meds: early results on health care use in the POPPY study
1 June 2015. Related: Conference reports, Ageing and life expectancy.
Other short reports from BHIVA:
1 June 2015. Related: Conference reports, Antiretrovirals, Paediatric care, Basic science and immunology.
2015 Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle
1 June 2015. Related: Conference reports.
Elvitegravir in children and adolescents
1 June 2015. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
PK of ARVs in pregnancy: rilpivirine, etravirine and raltegravir
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
HIV and cardiovascular disease
1 June 2015. Related: Conference reports, Coinfections and complications.
5th International Workshop on HIV & Women
, 21-22 February 2015, Seattle, Washington
1 June 2015. Related: Conference reports.
Pharmacokinetics in pregnancy: darunavir/r and etravirine
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy, PK and drug interactions.
Low prolactin and high 20alpha-HSD might contribute to ART-associated progesterone deficits in pregnancy
1 June 2015. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Pregnancy rates among women using ART and hormonal contraceptives in Kenya
1 June 2015. Related: Conference reports, Antiretrovirals, Pregnancy.
Adolescents at increased risk of vertical transmission and poor pregnancy outcome in South Africa
1 June 2015. Related: Conference reports, Women's health, Pregnancy.
Gender difference in virological response to ART
1 June 2015. Related: Conference reports, Antiretrovirals, Women's health.
Generic dolutegravir submitted to FDA for tentative approval
1 June 2015. Related: Antiretrovirals, Treatment access.
Lopinavir/ritonavir pellets tentatively approved by the FDA
1 June 2015. Related: Treatment access.
EMA approves coformulated atazanavir/cobicistat
1 June 2015. Related: Antiretrovirals.
Dual F/TAF formulation under evaluation by EMA
1 June 2015. Related: Antiretrovirals.
US guidelines shift to integrase-based combinations for first-line treatment (2015): Atripla relegated due to side effects
1 June 2015. Related: Guidelines.